An observational study in Pancreatic Neuroendocrine Tumor, sponsored by Francesco De Cobelli. Completed at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Francesco De Cobelli · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Adenoma, Islet Cell with a site in Italy — 3 open to participants now, 6 under way, 1 of them phase 3. Adenoma, Islet Cell · Italy.
Among the 11 studies in Adenoma, Islet Cell with a site in Italy, this one is the only one that started in 2019, is one of 6 observational ones, and was the 4th registered.
113 studies on the registry are indexed under Adenoma, Islet Cell; 30 are open to participants now.
Browse Adenoma, Islet Cell studies →3 of the 11 studies in Adenoma, Islet Cell with a site in Italy are open now. Recruiting first, the newest first:
Exelixis · Sites in Italy, United States, Australia and 15 more countries
Ages 18+
IRCCS San Raffaele · Sites in Italy
Ages 18+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Australia and 19 more countries
Ages 12+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 24 Adenoma, Islet Cell studies recruiting now, 17 (71%) set no upper age limit and 2 (8%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 1
First in 2006; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is close to the median of 70 across 31 observational studies indexed under Adenoma, Islet Cell.
Median enrollment 160 across the 5 interventional studies, 70 across the 6 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 11 have an industry lead sponsor. The 10 most frequent:
Francesco De Cobelli is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Francesco De Cobelli has 1 study filed under Adenoma, Islet Cell — fewer than ten, so there is no comparison to draw.
1 of the studies in Adenoma, Islet Cell with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07817225Massimo FalconiOptimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation | 2027-09-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Adenoma, Islet Cell with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to quantify inter-observer variability in delineating pancreatic neuroendocrine neoplasm (PanNEN) on Computerized Tomography (CT) images and its impact on radiomic features (RF), subsequently to this determination, to use CT texture analysis to predict, histological characteristics of PanNEN on CT scans.
CT imaging is the most widely used modality for studying radiomic features due to its ability to assess tissue density, shape, texture and size before, during and after therapy. To the best of the investigator's knowledge, the impact of inter-observer delineation variability on the reliability of CT RF for PanNEN patients, including Hounsfield unit (HU) values-, shape-, and texture-based features, has not yet been assessed. One this has been determined, an additional evaluation will be conducted to correlate the morphologically observed images with their histopathological characteristics.
The ultimate potential objective of this research is to identify and predict characteristics of aggressiveness of PanNEN in CT scans.
Monocentric, retrospective, observational study. Subjects who fulfill the inclusion criteria will be randomly chosen from our Institutional data-base. Thirty patients will be used to evaluate inter-observer variability and forty patients will be used to evaluate histological characteristics on CT-scans with and without contrast agent).
Imaged based and clinical variables will be used to construct an overall status of the patient.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated. In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be. Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated.
Interobserver variability in delineating panNENs on CT
Asses inter-observer variability on CT- scans (with contrast alone)
Time frame: 6 months
Use CT texture analysis to predict, histological characteristics of PanNEN on CT scans
Evaluate histological characteristics on CT-scans with and without contrast agent in a group of subjects
Time frame: 6 months
Plan to share: No
Ran from Mar 2019 to primary completion in May 2019, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Francesco De Cobelli